TempraMed News
8 articles
TempraMed to Support Beyond Type 1's Beyond Type Run Team at the 2025 TCS New York City Marathon
TempraMed Technologies Ltd., a leader in temperature-controlled medication storage solutions, has announced an in-kind partnership with Beyond Type 1 for the 2025 TCS New York City Marathon initiative, Beyond Type Run. This partnership supports 55 runners, many living with diabetes, by ensuring their medications are protected during the marathon. TempraMeds involvement aligns with its mission to empower the diabetes community through innovation and advocacy. The company offers FDA-registered products like VIVI Cap and VIVI Epi, and is expanding its smart technology platform. This partnership highlights TempraMeds commitment to enhancing medication protection and adherence globally.
Partners
TempraMed Announces Private Placement of up to C$2.5 Million
TempraMed Technologies Ltd., a leader in temperature-controlled medication storage solutions, announced a non-brokered private placement to raise up to C$2.5 million. The funds will be used for new inventory, product development, and scaling the sales and marketing division globally. Each unit in the offering includes one common share and one share purchase warrant, with the warrant allowing the purchase of an additional share at C$1.00 within 18 months. The closing of the offering is expected by November 5, 2025. TempraMeds products, such as VIVI Cap and VIVI Epi, are FDA-registered and designed to maintain the effectiveness of temperature-sensitive medications.
Investment
Canadian Securities Exchange Welcomes Listing of TempraMed Technologies Ltd.
TempraMed Technologies Ltd., an Israeli company specializing in temperature-controlled medication storage solutions, has been listed on the Canadian Securities Exchange (CSE) under the ticker symbol VIVI. The company completed a C$7.4 million private placement, issuing approximately 51.7 million common shares. This public listing is expected to provide TempraMed with access to a broader community of investors and valuable growth capital, enabling the company to accelerate its global expansion. TempraMeds innovative solutions aim to help pharmacies and customers manage temperature-sensitive medications effectively. The listing marks a significant milestone in the companys journey, as it joins the CSEs cohort of emerging life sciences companies.
PIPE/PO
New VIVI Epi device from TempraMed affords first-of-its-kind case protection for EpiPens against light and temperatures extremes
TempraMed is introducing the VIVI Epi, a new protection device for the EpiPen. The device is designed to protect Epinephrine from extreme temperatures and light. It will provide all-day, go anywhere protection for millions of allergy sufferers. The VIVI Epi will also be useful for institutions that need emergency interventions for anaphylactic events. The device meets the criteria for storing Epinephrine and is TSA compliant. It uses thermal insulation and control electronics to prevent degradation of the medication. TempraMeds mission is to create hassle-free solutions that help patients live better lives.
Customers
TempraMed introduces new-generation insulin protection device with first and only reusable temperature shield Cap | BioSpace
TempraMed is launching a new-generation insulin pen-cap temperature shield called VIVI Cap multi-model. The product provides temperature protection for in-use insulin, ensuring its efficacy and convenience for patients with diabetes. The VIVI Cap is self-contained, lightweight, and easy to use, with a built-in temperature sensor and indicator. It fits in a purse or pocket, allowing patients to carry it anywhere. The shield prevents insulin from being compromised by extreme temperatures, which can reduce its effectiveness and lead to adverse side effects. The VIVI Cap uses special thermal insulation and control electronics to maintain the temperature. TempraMed aims to create hassle-free solutions that help patients live better lives by protecting their medication.
Customers
TempraMed's VIVI Cap 1 is changing the way people who inject insulin live their lives
TempraMed has launched the VIVI Cap 1, a reusable insulin pen cap that keeps diabetes insulin at a safe temperature. The product helps protect insulin from temperature damage, ensuring better blood sugar control for patients. The VIVI Cap 1 is FDA registered and CE marked, and it operates without user intervention. TempraMed aims to provide hassle-free solutions for managing and controlling medications, allowing patients to live safer and more spontaneous lives. The company is led by a team of experts in the medical and diabetes fields.
Customers
10 breakthrough health techs emerging from Israel
CorNeat Vision and PixCell Medical were named the winners of the Biomed Startup of the Year competition at Israels MIXiii-Biomed conference. CorNeat Vision has developed an artificial cornea implant that could help millions of people suffering from corneal diseases. PixCell Medical is developing a low-cost portable hematology analyzer that performs a complete blood count at the point of care. The conference showcased 45 startups developing healthcare products in various fields. Other notable startups included SpacePharma, NovaSight, Alpha Tau Medical, Neurosteer, Brainvivo, TempraMed, E-Motion Medical, and BarimOte.
InvestmentExpand
TempraMed: New Insulin Pen Cooling Caps for Diabetes
Companion Medical has launched InPen, a Bluetooth-enabled insulin pen that works with a smartphone app to calculate and track insulin doses. The app can also suggest doses to correct high blood sugar levels and can create reports on insulin use and carbohydrate intake. The pen is refillable and can accept Humalog or Novolog penfill cartridges. The pen and app were cleared by the FDA in 2016 and were launched in the US in late 2017. The retail price for the system is just under $800, but Companion Medical is working to increase insurance coverage.
CustomersExpand
